2019
DOI: 10.1158/2326-6066.cir-18-0711
|View full text |Cite
|
Sign up to set email alerts
|

IRF1 Inhibits Antitumor Immunity through the Upregulation of PD-L1 in the Tumor Cell

Abstract: Multiple studies have associated the transcription factor IRF1 with tumor-suppressive activities. Here, we report an opposite tumor cell-intrinsic function of IRF1 in promoting tumor growth. IRF1-deficient tumor cells showed reduced tumor growth in MC38 and CT26 colon carcinoma and B16 melanoma mouse models. This reduction in tumor growth was dependent on host CD8 þ T cells. Detailed profiling of tumor-infiltrating leukocytes did not show changes in the various T-cell and myeloid cell populations. However, CD8… Show more

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

4
44
0
4

Year Published

2019
2019
2022
2022

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 70 publications
(52 citation statements)
references
References 38 publications
4
44
0
4
Order By: Relevance
“…[ 43 ] A recent experiment reported that IRF1-deficient tumors exhibited enhanced cytotoxicity of CD8+ T cells through downregulation of PD-L1 expression. [ 44 ] The aforementioned results imply the presence of a mechanism to explain the limited efficacy of PD-1/PD-L1 checkpoint inhibitors. Further investigation is warranted to confirm this conjecture.…”
Section: Resultsmentioning
confidence: 99%
“…[ 43 ] A recent experiment reported that IRF1-deficient tumors exhibited enhanced cytotoxicity of CD8+ T cells through downregulation of PD-L1 expression. [ 44 ] The aforementioned results imply the presence of a mechanism to explain the limited efficacy of PD-1/PD-L1 checkpoint inhibitors. Further investigation is warranted to confirm this conjecture.…”
Section: Resultsmentioning
confidence: 99%
“…In parallel, the overexpression of the NOD-like receptor CARD domain-containing 5 (NLRC5) in melanoma cells enhances antitumor immunity by increasing the expression of MHC class I genes and presentation of tumor antigens [ 28 ]. Moreover, Irf1 , Ifitm3 , and Sp100 are involved in the interferon-mediated response that plays a role in antitumor immunity in melanoma [ 29 , 30 ]. DRAM1 (DNA damage-regulated autophagy modulator 1) and RTN1 (reticulon 1) are autophagy-inducing factors [ 31 ].…”
Section: Resultsmentioning
confidence: 99%
“…Many studies reported that IRF1 is closely related to tumor inhibition. CD8 + T cells in IRF1-de cient melanoma showed increased cytotoxicity, the expression of PD-L1 was up-regulated, and tumor growth was more easily restored [32] . LAG3 is the third alternative inhibitory receptor targeted in tumor microenvironment, which has attracted much attention and research in clinical trials [33] .…”
Section: Discussionmentioning
confidence: 99%